HRP20191348T1 - Aminosteroidi za liječenje bolesti povezanih s ptp1b - Google Patents
Aminosteroidi za liječenje bolesti povezanih s ptp1b Download PDFInfo
- Publication number
- HRP20191348T1 HRP20191348T1 HRP20191348TT HRP20191348T HRP20191348T1 HR P20191348 T1 HRP20191348 T1 HR P20191348T1 HR P20191348T T HRP20191348T T HR P20191348TT HR P20191348 T HRP20191348 T HR P20191348T HR P20191348 T1 HRP20191348 T1 HR P20191348T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- treatment
- tyrosine
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 9
- 201000010099 disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 23
- 150000003839 salts Chemical class 0.000 claims 14
- 208000035475 disorder Diseases 0.000 claims 8
- 101001087394 Homo sapiens Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 claims 7
- 241000124008 Mammalia Species 0.000 claims 7
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 claims 7
- 230000002401 inhibitory effect Effects 0.000 claims 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (16)
1. Spoj ili njegova farmaceutski prihvatljiva sol izabrana u grupi koja se sastoji od:
2. Spoj ili njegova farmaceutski prihvatljiva sol sukladno zahtjevu 1, gdje je spoj:
3. Spoj ili njegova farmaceutski prihvatljiva sol sukladno zahtjevu 1, gdje je spoj:
4. Spoj ili njegova farmaceutski prihvatljiva sol sukladno zahtjevu 1, gdje je spoj:
5. Spoj ili njegova farmaceutski prihvatljiva sol sukladno zahtjevu 1, gdje je spoj:
6. Spoj ili njegova farmaceutski prihvatljiva sol sukladno zahtjevu 1, gdje je spoj:
7. Spoj ili njegova farmaceutski prihvatljiva sol sukladno zahtjevu 1, gdje je spoj:
8. Farmaceutski spoj koji sadrži spoj iz bilo kojeg od zahtjeva od 1 do 7 i farmaceutski prihvatljiv razrjeđivač ili nosač.
9. Spoj sukladno zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, za uporabu u liječenju poremećaja kod sisavaca posredstvom inhibicije protein-tirozin-fosfataze PTP1B.
10. Spoj sukladno zahtjevu 2 ili njegova farmaceutski prihvatljiva sol, za uporabu u liječenju poremećaja kod sisavaca posredstvom inhibicije protein-tirozin-fosfataze PTP1B.
11. Spoj sukladno zahtjevu 3 ili njegova farmaceutski prihvatljiva sol, za uporabu u liječenju poremećaja kod sisavaca posredstvom inhibicije protein-tirozin-fosfataze PTP1B.
12. Spoj sukladno zahtjevu 4 ili njegova farmaceutski prihvatljiva sol, za uporabu u liječenju poremećaja kod sisavaca posredstvom inhibicije protein-tirozin-fosfataze PTP1B.
13. Spoj sukladno zahtjevu 5 ili njegova farmaceutski prihvatljiva sol, za uporabu u liječenju poremećaja kod sisavaca posredstvom inhibicije protein-tirozin-fosfataze PTP1B.
14. Spoj sukladno zahtjevu 6 ili njegova farmaceutski prihvatljiva sol, za uporabu u liječenju poremećaja kod sisavaca posredstvom inhibicije protein-tirozin-fosfataze PTP1B.
15. Spoj sukladno zahtjevu 7 ili njegova farmaceutski prihvatljiva sol, za uporabu u liječenju poremećaja kod sisavaca posredstvom inhibicije protein-tirozin-fosfataze PTP1B.
16. Spoj za uporabu sukladno bilo kojem od zahtjeva od 9 do 15, gdje je poremećaj izabran iz grupe koja se sastoji od dijabetesa, pretilosti i visokog kolesterola.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261636252P | 2012-04-20 | 2012-04-20 | |
| PCT/US2013/037330 WO2013158970A2 (en) | 2012-04-20 | 2013-04-19 | Aminosteroids for the treatment of a ptp1b associated disease |
| EP13721176.9A EP2838907B1 (en) | 2012-04-20 | 2013-04-19 | Aminosteroids for the treatment of a ptp1b associated disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191348T1 true HRP20191348T1 (hr) | 2019-10-18 |
Family
ID=48325893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191348TT HRP20191348T1 (hr) | 2012-04-20 | 2019-07-25 | Aminosteroidi za liječenje bolesti povezanih s ptp1b |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US9546194B2 (hr) |
| EP (2) | EP3556765B1 (hr) |
| JP (4) | JP6165843B2 (hr) |
| KR (3) | KR101963312B1 (hr) |
| AU (3) | AU2013249111B2 (hr) |
| CA (1) | CA2870671C (hr) |
| DK (1) | DK2838907T3 (hr) |
| ES (1) | ES2736310T3 (hr) |
| HK (1) | HK1205516A1 (hr) |
| HR (1) | HRP20191348T1 (hr) |
| HU (1) | HUE044769T2 (hr) |
| MX (2) | MX367255B (hr) |
| PL (1) | PL2838907T3 (hr) |
| PT (1) | PT2838907T (hr) |
| TR (1) | TR201911039T4 (hr) |
| WO (1) | WO2013158970A2 (hr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2838907T3 (pl) | 2012-04-20 | 2019-12-31 | Ohr Pharmaceutical, Inc. | Aminosteroidy do leczenia choroby związanej z PTP1B |
| US10040817B2 (en) | 2013-10-03 | 2018-08-07 | Enterin Laboratories, Inc. | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same |
| GB201700567D0 (en) | 2017-01-12 | 2017-03-01 | Genagon Therapeutics Ab | Therapeutic agents |
| MA50094A (fr) | 2017-09-08 | 2020-07-15 | Enterin Inc | Méthodes de traitement des troubles du sommeil, des perturbations du sommeil et de symptômes associés à l'aide de compositions d'aminostérol |
| CN107802626B (zh) * | 2017-10-11 | 2020-01-21 | 南昌大学 | 降血糖组合物及其制备方法、用途 |
| AU2018360845B2 (en) * | 2017-11-06 | 2024-05-02 | Cold Spring Harbor Laboratory | Method and compositions for forming a copper-containing complex and uses thereof |
| AU2019242557A1 (en) * | 2018-03-27 | 2020-10-15 | Enterin, Inc. | Methods and compositions for treating hallucinations and conditions related to the same |
| US20210261602A1 (en) * | 2018-07-20 | 2021-08-26 | Cold Spring Harbor Laboratory | (pyridinylmethyl)butanediamine derivatives that chelate copper |
| EP4007765A4 (en) * | 2019-08-02 | 2023-08-23 | Enterin, Inc. | HUMAN SQUALAMIN DERIVATIVES, COMPOSITIONS CONTAINING THEM, AND METHODS OF USE THEREOF |
| JP2022543242A (ja) * | 2019-08-02 | 2022-10-11 | エンターイン、 インコーポレイテッド | ヒトアミノステロールｅｎｔ－０３化合物、それを含む関連組成物、およびそれを使用する方法 |
| WO2023230593A1 (en) | 2022-05-27 | 2023-11-30 | Cold Spring Harbor Laboratory | Ptp1b inhibitors for treating lung injury |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2403683A (en) * | 1942-04-25 | 1946-07-09 | Relchstein Tadeus | Compounds of the cyclopentanopolyhydrophenanthrene series and process of making same |
| US3636210A (en) * | 1968-02-02 | 1972-01-18 | Merck & Co Inc | Cholanic acid and cholenic acid compositions and method of treatment |
| JPS60181096A (ja) * | 1984-02-28 | 1985-09-14 | Tokyo Tanabe Co Ltd | 胆汁酸の精製方法 |
| IT1255450B (it) * | 1992-06-30 | 1995-10-31 | Montefarmaco Spa | Uso di acidi biliari come agenti antivirali |
| AU6392894A (en) * | 1993-02-26 | 1994-09-14 | Magainin Pharmaceuticals, Inc. | Chemical synthesis of squalamine |
| JP3546886B2 (ja) * | 1993-03-10 | 2004-07-28 | ジェネーラ コーポレーション | ステロイド誘導体、それらを含む薬剤組成物、及び抗生物質又は消毒薬としてのそれらの使用 |
| US5856535A (en) * | 1994-08-18 | 1999-01-05 | Magainin Pharmaceuticals, Inc. | Aminosterol ester compounds |
| DE69631527T2 (de) | 1995-06-07 | 2004-09-23 | Genaera Corp. | Aminosterinverbindungen als inhibitoren der natrium/proton-pump, pharmazeutische methoden und präparaten davon |
| US5792635A (en) | 1995-06-07 | 1998-08-11 | Magainin Pharmaceuticals, Inc. | Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine |
| US7410959B1 (en) * | 2000-07-13 | 2008-08-12 | Genaera Corporation | Therapeutic uses for aminosterol compounds |
| JP2003509430A (ja) | 1999-09-10 | 2003-03-11 | ノボ ノルディスク アクティーゼルスカブ | プロテインチロシンホスファターゼ（ｐｔｐアーゼ）のモジュレーター |
| DE60028791T2 (de) | 1999-09-10 | 2007-05-24 | Novo Nordisk A/S | Modulatoren der protein tyrosin phosphatase (ptpases) |
| AU7476800A (en) | 1999-09-10 | 2001-04-10 | Novo Nordisk A/S | Method of inhibiting protein tyrosine phosphatase 1b and/or t-cell protein tyrosine phosphatase and/or other ptpases with an asp residue at position 48 |
| JP2004506599A (ja) * | 1999-12-09 | 2004-03-04 | ジェネーラ・コーポレーション | 喘息および関連疾患を含むアトピー性アレルギーを処置するための標的としての喘息関連因子 |
| EP1575981B1 (en) * | 2002-12-24 | 2009-06-10 | The University of British Columbia | Angiogenic acting tri-sulphate steroids and uses thereof |
| JP2006165843A (ja) * | 2004-12-06 | 2006-06-22 | Matsushita Electric Ind Co Ltd | 画像処理装置 |
| EP2051716A1 (en) | 2006-04-21 | 2009-04-29 | Genaera Corporation | Induction of weight loss and the selective inhibition of ptp1b |
| TW200927755A (en) * | 2007-09-06 | 2009-07-01 | Genaera Corp | A method for treating diabetes |
| KR101260221B1 (ko) * | 2011-12-01 | 2013-05-06 | 주식회사 엘지화학 | 마스크 |
| PL2838907T3 (pl) * | 2012-04-20 | 2019-12-31 | Ohr Pharmaceutical, Inc. | Aminosteroidy do leczenia choroby związanej z PTP1B |
-
2013
- 2013-04-19 PL PL13721176T patent/PL2838907T3/pl unknown
- 2013-04-19 WO PCT/US2013/037330 patent/WO2013158970A2/en active Application Filing
- 2013-04-19 PT PT13721176T patent/PT2838907T/pt unknown
- 2013-04-19 KR KR1020167019758A patent/KR101963312B1/ko active IP Right Grant
- 2013-04-19 TR TR2019/11039T patent/TR201911039T4/tr unknown
- 2013-04-19 HU HUE13721176 patent/HUE044769T2/hu unknown
- 2013-04-19 AU AU2013249111A patent/AU2013249111B2/en active Active
- 2013-04-19 EP EP19175554.5A patent/EP3556765B1/en active Active
- 2013-04-19 EP EP13721176.9A patent/EP2838907B1/en active Active
- 2013-04-19 US US14/394,789 patent/US9546194B2/en active Active
- 2013-04-19 KR KR1020147031485A patent/KR20150003798A/ko active Application Filing
- 2013-04-19 KR KR1020197008179A patent/KR102057812B1/ko active IP Right Grant
- 2013-04-19 DK DK13721176.9T patent/DK2838907T3/da active
- 2013-04-19 JP JP2015507213A patent/JP6165843B2/ja active Active
- 2013-04-19 ES ES13721176T patent/ES2736310T3/es active Active
- 2013-04-19 MX MX2014012619A patent/MX367255B/es active IP Right Grant
- 2013-04-19 CA CA2870671A patent/CA2870671C/en active Active
-
2014
- 2014-10-17 MX MX2019009539A patent/MX2019009539A/es unknown
-
2015
- 2015-06-25 HK HK15106046.4A patent/HK1205516A1/xx unknown
-
2016
- 2016-10-06 US US15/286,646 patent/US20170129914A1/en not_active Abandoned
-
2017
- 2017-05-02 JP JP2017091568A patent/JP6457010B2/ja active Active
-
2018
- 2018-10-31 AU AU2018256561A patent/AU2018256561B2/en active Active
- 2018-12-19 JP JP2018237492A patent/JP2019059781A/ja not_active Withdrawn
-
2019
- 2019-03-12 US US16/299,872 patent/US10556923B2/en active Active
- 2019-07-25 HR HRP20191348TT patent/HRP20191348T1/hr unknown
-
2020
- 2020-01-30 US US16/777,253 patent/US11434257B2/en active Active
- 2020-06-05 AU AU2020203736A patent/AU2020203736B2/en active Active
-
2021
- 2021-01-25 JP JP2021009651A patent/JP2021073250A/ja active Pending
-
2022
- 2022-07-29 US US17/877,498 patent/US20230203088A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191348T1 (hr) | Aminosteroidi za liječenje bolesti povezanih s ptp1b | |
| HRP20192202T1 (hr) | Acc inhibitori i njihove upotrebe | |
| HRP20171648T1 (hr) | Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze | |
| JP2012107034A5 (hr) | ||
| UY34918A (es) | Nuevos ácidos 5-aminotetrahidroquinolin-2-carboxílicos y su uso | |
| BR112014026285A8 (pt) | oligonucleotídeos moduladores de rna com características melhoradas para o tratamento de distúrbios neuromusculares | |
| JP2015504870A5 (hr) | ||
| JP2013181136A5 (ja) | ポリイミド前駆体組成物、ポリイミド成形体、及び画像形成装置 | |
| UY35771A (es) | Tienouracil-carboxamidas cíclicas y su uso | |
| JP2013523758A5 (hr) | ||
| BR112014016127A2 (pt) | sistemas espiroesteroidais com efeitos neuroativos e anti-inflamatórios, e, composição farmacêutica | |
| SMT201600334B (it) | Interferone beta per l'uso nel trattamento della malattia del tratto respiratorio inferiore causata da influenza | |
| JP2013059750A5 (hr) | ||
| 岡野光夫 | Turn to a Special Edition | |
| TH1501003557A (th) | "การใช้ของ 3-คาร์บอกซี-N-เอทิล-N,N-ไดเมทิลโพรพาน-1-อะมิเนียม หรือเกลือที่ยอมรับได้ทางเภสัชกรรมของสารนี้ในการรักษาของโรคหลอดเลือดแดงแข็ง(atherosclerosis)" | |
| TH133140S (th) | เก้าอี้ | |
| TH119602B (th) | ลวดลายจาน | |
| CN302443911S (zh) | 药枕（靠枕-3） | |
| TH38935S1 (th) | ลวดลายจาน | |
| TH38000S1 (th) | ลวดลายจาน | |
| TH123432S (th) | ลวดลายจาน | |
| TH38001S1 (th) | ลวดลายจาน | |
| TH53511S1 (th) | ลวดลายจาน | |
| TH38002S1 (th) | ลวดลายจาน | |
| TH112398A (th) | องค์ประกอบทางเภสัชกรรมสำหรับโรคพาร์กินสัน |